Neurocrine BiosciencesNBIX

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Biopharma focused on neurological and endocrine diseases (Ingrezza).

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$17.9B

Price

$176.93

Today

−2.0%

Return YTD

+27.3%

Return 1Y

+35.2%

P/E

26.8

P/S

5.8

P/B

5.3

Data as of 2026-07-10 · updates daily after U.S. close

Theme exposure

Neuro biotechNeurologyEndocrinologyCNS therapy

In the value chain

Products & services

Ingrezza (tardive dyskinesia)
Endocrine portfolio
CNS pipeline

Competitors

Teva
AbbVie
Sage Therapeutics

Risks

Ingrezza concentration
Clinical pipeline risk

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN Alnylam PharmaceuticalsALNY ModernaMRNA BiogenBIIB IncyteINCY

See where Neurocrine Biosciences sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →